Restoration of epithelial sodium channel function by synthetic peptides in pseudohypoaldosteronism type 1B mutants

Anita Willam, Mohammed Aufy, Susan Tzotzos, Heinrich Evanzin, Sabine Chytracek, Sabrina Geppert, Bernhard Fischer, Hendrik Fischer, Helmut Pietschmann, Istvan Czikora, Rudolf Lucas, Rosa Lemmens-Gruber, Waheed Shabbir

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The synthetically produced cyclic peptides solnatide (a.k.a. TIP or AP301) and its congener AP318, whose molecular structures mimic the lectin-like domain of human tumor necrosis factor (TNF), have been shown to activate the epithelial sodium channel (ENaC) in various cell- and animal-based studies. Loss-of-ENaC-function leads to a rare, life-threatening, salt-wasting syndrome, pseudohypoaldosteronism type 1B (PHA1B), which presents with failure to thrive, dehydration, low blood pressure, anorexia and vomiting; hyperkalemia, hyponatremia and metabolic acidosis suggest hypoaldosteronism, but plasma aldosterone and renin activity are high. The aim of the present study was to investigate whether the ENaC-activating effect of solnatide and AP318 could rescue loss-of-function phenotype of ENaC carrying mutations at conserved amino acid positions observed to cause PHA1B. The macroscopic Na+ current of all investigated mutants was decreased compared to wild type ENaC when measured in whole-cell patch clamp experiments, and a great variation in the membrane abundance of different mutant ENaCs was observed with Western blotting experiments. However, whatever mechanism leads to loss-of-function of the studied ENaC mutations, the synthetic peptides solnatide and AP318 could restore ENaC function up to or even higher than current levels of wild type ENaC. As therapy of PHA1B is only symptomatic so far, the peptides solnatide and AP318, which directly target ENaC, are promising candidates for the treatment of the channelopathy-caused disease PHA1B.

Original languageEnglish (US)
Article number85
JournalFrontiers in Pharmacology
Volume8
Issue numberFEB
DOIs
StatePublished - Feb 24 2017

Fingerprint

Pseudohypoaldosteronism
Epithelial Sodium Channels
Peptides
Hypoaldosteronism
Channelopathies
Wasting Syndrome
Failure to Thrive
Cyclic Peptides
Mutation
Hyperkalemia
Hyponatremia
Anorexia
Acidosis
Molecular Structure
Aldosterone
Dehydration
Renin
Lectins
Hypotension
Vomiting

Keywords

  • AP318
  • Amiloride-sensitive epithelial sodium channel (ENaC)
  • Lectin-like domain of tumor necrosis factor (TNF)
  • Pseudohypoaldosteronism type 1B (PHA1B)
  • Solnatide (AP301)
  • TIP peptides

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Restoration of epithelial sodium channel function by synthetic peptides in pseudohypoaldosteronism type 1B mutants. / Willam, Anita; Aufy, Mohammed; Tzotzos, Susan; Evanzin, Heinrich; Chytracek, Sabine; Geppert, Sabrina; Fischer, Bernhard; Fischer, Hendrik; Pietschmann, Helmut; Czikora, Istvan; Lucas, Rudolf; Lemmens-Gruber, Rosa; Shabbir, Waheed.

In: Frontiers in Pharmacology, Vol. 8, No. FEB, 85, 24.02.2017.

Research output: Contribution to journalArticle

Willam, A, Aufy, M, Tzotzos, S, Evanzin, H, Chytracek, S, Geppert, S, Fischer, B, Fischer, H, Pietschmann, H, Czikora, I, Lucas, R, Lemmens-Gruber, R & Shabbir, W 2017, 'Restoration of epithelial sodium channel function by synthetic peptides in pseudohypoaldosteronism type 1B mutants', Frontiers in Pharmacology, vol. 8, no. FEB, 85. https://doi.org/10.3389/fphar.2017.00085
Willam, Anita ; Aufy, Mohammed ; Tzotzos, Susan ; Evanzin, Heinrich ; Chytracek, Sabine ; Geppert, Sabrina ; Fischer, Bernhard ; Fischer, Hendrik ; Pietschmann, Helmut ; Czikora, Istvan ; Lucas, Rudolf ; Lemmens-Gruber, Rosa ; Shabbir, Waheed. / Restoration of epithelial sodium channel function by synthetic peptides in pseudohypoaldosteronism type 1B mutants. In: Frontiers in Pharmacology. 2017 ; Vol. 8, No. FEB.
@article{b52e8b12cb5947ce8cce1dc0ca1a6346,
title = "Restoration of epithelial sodium channel function by synthetic peptides in pseudohypoaldosteronism type 1B mutants",
abstract = "The synthetically produced cyclic peptides solnatide (a.k.a. TIP or AP301) and its congener AP318, whose molecular structures mimic the lectin-like domain of human tumor necrosis factor (TNF), have been shown to activate the epithelial sodium channel (ENaC) in various cell- and animal-based studies. Loss-of-ENaC-function leads to a rare, life-threatening, salt-wasting syndrome, pseudohypoaldosteronism type 1B (PHA1B), which presents with failure to thrive, dehydration, low blood pressure, anorexia and vomiting; hyperkalemia, hyponatremia and metabolic acidosis suggest hypoaldosteronism, but plasma aldosterone and renin activity are high. The aim of the present study was to investigate whether the ENaC-activating effect of solnatide and AP318 could rescue loss-of-function phenotype of ENaC carrying mutations at conserved amino acid positions observed to cause PHA1B. The macroscopic Na+ current of all investigated mutants was decreased compared to wild type ENaC when measured in whole-cell patch clamp experiments, and a great variation in the membrane abundance of different mutant ENaCs was observed with Western blotting experiments. However, whatever mechanism leads to loss-of-function of the studied ENaC mutations, the synthetic peptides solnatide and AP318 could restore ENaC function up to or even higher than current levels of wild type ENaC. As therapy of PHA1B is only symptomatic so far, the peptides solnatide and AP318, which directly target ENaC, are promising candidates for the treatment of the channelopathy-caused disease PHA1B.",
keywords = "AP318, Amiloride-sensitive epithelial sodium channel (ENaC), Lectin-like domain of tumor necrosis factor (TNF), Pseudohypoaldosteronism type 1B (PHA1B), Solnatide (AP301), TIP peptides",
author = "Anita Willam and Mohammed Aufy and Susan Tzotzos and Heinrich Evanzin and Sabine Chytracek and Sabrina Geppert and Bernhard Fischer and Hendrik Fischer and Helmut Pietschmann and Istvan Czikora and Rudolf Lucas and Rosa Lemmens-Gruber and Waheed Shabbir",
year = "2017",
month = "2",
day = "24",
doi = "10.3389/fphar.2017.00085",
language = "English (US)",
volume = "8",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",
number = "FEB",

}

TY - JOUR

T1 - Restoration of epithelial sodium channel function by synthetic peptides in pseudohypoaldosteronism type 1B mutants

AU - Willam, Anita

AU - Aufy, Mohammed

AU - Tzotzos, Susan

AU - Evanzin, Heinrich

AU - Chytracek, Sabine

AU - Geppert, Sabrina

AU - Fischer, Bernhard

AU - Fischer, Hendrik

AU - Pietschmann, Helmut

AU - Czikora, Istvan

AU - Lucas, Rudolf

AU - Lemmens-Gruber, Rosa

AU - Shabbir, Waheed

PY - 2017/2/24

Y1 - 2017/2/24

N2 - The synthetically produced cyclic peptides solnatide (a.k.a. TIP or AP301) and its congener AP318, whose molecular structures mimic the lectin-like domain of human tumor necrosis factor (TNF), have been shown to activate the epithelial sodium channel (ENaC) in various cell- and animal-based studies. Loss-of-ENaC-function leads to a rare, life-threatening, salt-wasting syndrome, pseudohypoaldosteronism type 1B (PHA1B), which presents with failure to thrive, dehydration, low blood pressure, anorexia and vomiting; hyperkalemia, hyponatremia and metabolic acidosis suggest hypoaldosteronism, but plasma aldosterone and renin activity are high. The aim of the present study was to investigate whether the ENaC-activating effect of solnatide and AP318 could rescue loss-of-function phenotype of ENaC carrying mutations at conserved amino acid positions observed to cause PHA1B. The macroscopic Na+ current of all investigated mutants was decreased compared to wild type ENaC when measured in whole-cell patch clamp experiments, and a great variation in the membrane abundance of different mutant ENaCs was observed with Western blotting experiments. However, whatever mechanism leads to loss-of-function of the studied ENaC mutations, the synthetic peptides solnatide and AP318 could restore ENaC function up to or even higher than current levels of wild type ENaC. As therapy of PHA1B is only symptomatic so far, the peptides solnatide and AP318, which directly target ENaC, are promising candidates for the treatment of the channelopathy-caused disease PHA1B.

AB - The synthetically produced cyclic peptides solnatide (a.k.a. TIP or AP301) and its congener AP318, whose molecular structures mimic the lectin-like domain of human tumor necrosis factor (TNF), have been shown to activate the epithelial sodium channel (ENaC) in various cell- and animal-based studies. Loss-of-ENaC-function leads to a rare, life-threatening, salt-wasting syndrome, pseudohypoaldosteronism type 1B (PHA1B), which presents with failure to thrive, dehydration, low blood pressure, anorexia and vomiting; hyperkalemia, hyponatremia and metabolic acidosis suggest hypoaldosteronism, but plasma aldosterone and renin activity are high. The aim of the present study was to investigate whether the ENaC-activating effect of solnatide and AP318 could rescue loss-of-function phenotype of ENaC carrying mutations at conserved amino acid positions observed to cause PHA1B. The macroscopic Na+ current of all investigated mutants was decreased compared to wild type ENaC when measured in whole-cell patch clamp experiments, and a great variation in the membrane abundance of different mutant ENaCs was observed with Western blotting experiments. However, whatever mechanism leads to loss-of-function of the studied ENaC mutations, the synthetic peptides solnatide and AP318 could restore ENaC function up to or even higher than current levels of wild type ENaC. As therapy of PHA1B is only symptomatic so far, the peptides solnatide and AP318, which directly target ENaC, are promising candidates for the treatment of the channelopathy-caused disease PHA1B.

KW - AP318

KW - Amiloride-sensitive epithelial sodium channel (ENaC)

KW - Lectin-like domain of tumor necrosis factor (TNF)

KW - Pseudohypoaldosteronism type 1B (PHA1B)

KW - Solnatide (AP301)

KW - TIP peptides

UR - http://www.scopus.com/inward/record.url?scp=85014262265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014262265&partnerID=8YFLogxK

U2 - 10.3389/fphar.2017.00085

DO - 10.3389/fphar.2017.00085

M3 - Article

AN - SCOPUS:85014262265

VL - 8

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - FEB

M1 - 85

ER -